2 results
Approved WMOCompleted
The primary objective is to show that eplerenone treatment reduces progression of disease in presymptomatic PLN R14del-carriers
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.